Novavax Shares Are Rising On Incremental COVID-19 Vaccine Related News

  • The European Medicines Agency (EMA) has begun evaluating an application for conditional marketing authorization for Novavax Inc's NVAX COVID-19 vaccine.
  • The protein-based vaccine candidate will be marketed in the European Union under the brand name Nuvaxovid.
  • Separately, Novavax and Serum Institute of India Pvt. Ltd (SII) announced that the Philippine Food and Drug Administration (FDA) had granted emergency use authorization (EUA) for Novavax's COVID-19 vaccine with Matrix-M adjuvant. 
  • The vaccine will be manufactured and marketed in the Philippines by SII under the brand name Covovax. The Novavax/SII vaccine has recently received EUA in Indonesia. 
  • The companies have also filed for emergency authorization in India and Emergency Use Listing (EUL) with the World Health Organization (WHO). 
  • Related Link: Novavax Concludes Filing For WHO's Emergency Use Listing For COVID-19 Vaccine.
  • Price Action: NVAX shares are up 10.10% at $187.68 during the market session on the last check Wednesday.
Loading...
Loading...
NVAX Logo
NVAXNovavax Inc
$7.7515.2%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
15.03
Growth
-
Quality
-
Value
45.69
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...